Treatment of Osteoporosis

Open access

Liječenje Osteoporoze

Osteoporoza je jedna od najčešćih metaboličkih bolesti i zahvaća 8 % do 10 % stanovništva. Budući da je prijelom najteža posljedica osteoporoze, vrlo je važno otkriti bolesnike koji imaju rizik nastanka prijeloma, dati im farmakološku terapiju i savjetovati im promjenu načina života. Nekoliko je lijekova pokazalo sposobnost smanjenja broja prijeloma kralježnice i/ili perifernog skeleta u bolesnika s osteoporozom. Antiresorptivni su lijekovi temelj terapije, ali su i anabolički lijekovi odnedavno proširili mogućnosti liječenja. Antiresorptivni lijekovi, estrogeni, selektivni modulatori estrogenskih receptora, bisfosfonati i kalcitonin, djeluju tako da smanjuju koštanu pregradnju. Paratireoidni hormon potiče novo stvaranje kosti popravljajući arhitekturu i gustoću kosti. Stroncijev ranelat smanjuje rizik osteoporotičnih prijeloma djelujući na oboje - smanjenje razgradnje i povećanje izgradnje kosti. Druga potencijalna liječenja osteoporoze također su opisana u ovome članku.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • Simonelli C Weiss TW Morancey J Swanson L Chen YT. Prevalence of vitamin D inadequacy in a minimal trauma fracture population. Curr Med Res Opin 2005;21:1069-74.

  • Jilka RL Hangoc G Girasole G Passeri G Williams DC Abrams JS Boyce B Broxmeyer H Manolagas SC. Increased osteoclast development after estrogen lossmediation by interleukin-6. Science 1992;257:88-91.

  • Ammann P Rizzoli R Bonjour JP Bourrin S Meyer JM Vassalli P Garcia I. Transgenic mice expressing soluble tumor necrosis factor-receptor are protected against bone loss caused by estrogen deficiency. J Clin Invest 1997;99:1699-703.

  • Oursler MJ Osdoby P Pyfferoen J Riggs BL Spelsberg TC. Avian osteoclasts as estrogen target cells. Proc Natl Acad Sci USA 1991;88:6613-7.

  • Pennisi E. Drugs' link to genes reveals estrogen's many sides. Science 1996;273:1171.

  • Tzukerman MT Esty A Santiso-Mere D Danielian P Parker MG Stein RB Pike JW McDonnell DP. Human estrogen receptor transcriptional capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Mol Endocrinol 1994;8:21-30.

  • Manson JE Hsia J Johnson KC Rossouw JE Assaf AR Lasser NL Trevisan M Black HR Heckbert SR Detrano R Strickland OL Wong ND Crouse JR Stein E Cushman M; Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. New Engl J Med 2003;349: 523-34.

  • Udell JA Fischer MA Brookhart MA Solomon DH Choudhry NK. Effect of the women's health initiative on osteoporosis therapy and expenditure in Medicaid. J Bone Miner Res 2006;21:765-71.

  • Hulley S Grady D Bush T Furberg C Herrington D Riggs B Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-13.

  • Nelson HD Humphrey LL Nygren P Teutsch SM Allan JD. Postmenopausal hormone replacement therapy: scientific review. JAMA 2002;288:872-81.

  • Hays J Ockene JK Brunner RL Kotchen JM Manson JE Patterson RE Aragaki AK Shumaker SA Brzyski RG LaCroix AZ Granek IA Valanis BG. Effects of estrogen plus progestin on health-related quality of life. New Engl J Med 2003;348:1839-54.

  • Black LJ Sato M Rowley ER. Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 1994;93:63-9.

  • Delmas PD Bjarnason NH Mitlak BH Ravoux AC Shah AS Huster WJ Draper M Christiansen C. Effects of raloxifene on bone mineral density serum cholesterol concentrations and uterine endometrium in postmenopausal women. New Engl J Med 1997;337:1641-7.

  • Sambrook P. Who will benefit from treatment with selective estrogen receptor modulators (SERMs)? Best Pract Res Clin Rheumatol 2005;19:975-81.

  • Yang NN Venugopalan M Hardikar S Glasebrook A. Identification of an estrogen response element activated by metabolites of 17β-estradiol raloxifene. Science 1996;273:1222-5.

  • Onate SA Tsai SY Tsai MJ O'Malley BW. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 1995;270:1354-7.

  • Barrett-Connor E Mosca L Collins P i sur. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. New Engl J Med 2006;355:125-37.

  • Bevers TB. Raloxifene and the prevention of breast cancer. Expert Opin Pharmacother 2006;7:2301-7.

  • Ettinger B Black DM Mitlak BH Knickerbocker RK Nickelsen T Genant HK Christiansen C Delmas PD Zanchetta JR Stakkestad J Gluer CC Krueger K Cohen FJ Eckert S Ensrud Ke Avioli LV Lips P Cummings SR. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with Raloxifene: results from a 3-year randomized clinical trial. JAMA 1999;281:2189-97.

  • Martino S Cauley JA Barrett-Connor E Powles TJ Mershon J Disch D Secrest RJ Cummings SR; CORE Investigators. (CORE Investigators): Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004;96:1751-61.

  • Storm T Thamsborg G Steiniche T Genant HK Sorensen OH. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. New Engl J Med 1990;322:1265-71.

  • Benford HL Frith JC Auriola S Monkkonen J Rogers MJ. Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Mol Pharmacol 1999;56:131-40.

  • Lehenkari PP Kellinsalmi M Napankangas JP Ylitalo KV Monkkonen J Rogers MJ Azhayev A Vananen HK Hassinen IE. Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable adenine-containing metabolite. Mol. Pharmacol 2002;61:1255-62.

  • Bergstrom JD Bostedor RG Masarachia PJ Reszka AA Rodan G. Alendronate is a specific nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys 2000;373:231-41.

  • Luckman SP Hughes DE Coxon FP Graham R Russell G Rogers MJ. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent posttranslational prenylation of GTP-binding proteins including Ras. J Bone Miner Res 1998;13:581-9.

  • van Beek E Pieterman E Cohen L Lowik C Papapoulos S. Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo. Biochem Biophys Res Commun 1999;255:491-4.

  • Rodan GA Reszka AA. Bisphosphonate mechanism of action. Curr Mol Med 2002;2:571-7.

  • Russell RG Croucher PI Rogers MJ. Bisphosphonates: pharmacology mechanisms of action and clinical uses. Osteoporos Int 1999;9(Suppl 2):S66-80.

  • Iwamoto J Takeda T Sato Y. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis. Curr Med Res Opin 2006;22:919-28.

  • Recker RR Gallagher R MacCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 2005;80:856-61.

  • Bone HG Hosking D Devogelaer JP Tucci JR Emkey RD Tonino RP Rodriguez-Portales JA Downs RW Gupta J Santora AC Liberman UA. Alendronate Phase III Osteoporosis Treatment Study Group. Ten years' experience with alendronate for osteoporosis in postmenopausal women. New Engl J Med 2004;350:1189-99.

  • Hosking D Chilvers CE Christiansen C Ravn P Wasnich R Ross P McClung M Balske A Thompson D Daley M Yates AJ. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early postmenopausal intervention cohort study group. New Engl J Med 1998;338:485-92.

  • Sambrook PN Geusens P Ribot C Solimano JA Ferrer-Barriendos J Gaines K Verbruggen N Melton ME. Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International. J Intern Med 2004;255:503-11.

  • Woo SB Hellstein JW Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006;16:753-61.

  • de Nijs RN Jacobs JW Lems WF Laan RF Algra A Huisman AM Buskens E de Laet CE Oostveen AC Geusens PP Bruyn GA Dijkmans BA Bijlsma JW. STOP Investigators. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. New Engl J Med 2006;355:675-84.

  • Fogelman I Ribot C Smith R Ethgen D Sod E Reginster JY. Risedronate reverses bone loss in postmenopausal women with low bone mass: results form a multinational double-blind placebocontrolled trial. J Clin Endocrinol Metab 2000;85:1895-900.

  • Brown JP Kendler DL McClung MR Emkey RD Adachi JD Bolognese MA Li Z Balske A Lindsay R. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 2002;71:103-11.

  • Harris ST Watts NB Genant HK McKeever CD Hangartner T Keller M Chesnut CH 3rd Brown J Eriksen EF Hoseyni MS Axelrod DW Miller PD. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. JAMA 1999;282:1344-52.

  • Reginster J Minne HW Sorensen OH Hooper M Roux C Brandi ML Lund B Ethgen D Pack S Roumagnac I Eastell R. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000;11:83-91.

  • Ravn P Clemmesen B Riis BJ Christiansen C. The effect on bone mass and bone markers of different doses of ibandronate: A new bisphosphonate for prevention and treatment of postmenopausal osteoporosis. A 1-year randomized double-blind placebo-controlled dose-ranging study. Bone 1996;19:527-33.

  • Riis BJ Ise J von Stein T Bagger Y Christiansen C. Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis. J Bone Miner Res 2001;16:1871-8.

  • Thiebaud D Burckhardt P Kriegbaum H Huss H Mulder H Juttmann JR Schoter KH. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med 1997;103:298-307.

  • Miller PD McClung MR Macovei L Stakkestad JA Luckey M Bonvoisin B Reginster JY Recker RR Hughes C Lewiecki EM Felsenberg D Delmas PD Kendler DL Bolognese MA Mairon N Cooper C. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 2005;20:1315-22.

  • Silverman SL. Calcitonin. Endocrinol Metab Clin North Am 2003;32:273-84.

  • Chambers TJ Moore A. The sensitivity of isolated osteoclasts to morphological transformation by calcitonin. J Clin Endocrinol Metab 1983;57:819-24.

  • Mehta NM Malootian A Gilligan JP. Calcitonin for osteoporosis and bone pain. Curr Pharm Des 2003;9:2659-76.

  • Ofluoglu D Akyuz G Unay O Kayhan O. The effect of calcitonin on beta-endorphin levels in postmenopausal osteoporotic patients with back pain. Clin Rheumatol 2007;26:44-9.

  • Chesnut CH 3rd Silverman S Andriano K Genant H Gimona A Harris S Kiel D LeBoff M Maricic M Miller P Moniz C Peacock M Richardson P Watts N Baylink D. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000;109:267-76.

  • Lyritis GP Trovas G. Analgesic effects of calcitonin. Bone 2002;30:71-4.

  • Miyauchi A Notoya K Taketomi S. Novel ipriflavone receptors coupled to calcium influx regulate osteoclast differentiation and function. Endocrinology 1996;137:3544-50.

  • Alexandersen P Toussaint A Christiansen C Devogelaer JP Roux C Fechtenbaum J Gennari C Reginster JY; Ipriflavone Multicenter European Fracture Study. Ipriflavone in the treatment of postmenopausal osteoporosis: a randomized controlled trial. JAMA 2001;285:1482-8.

  • Darby AJ Meunier PJ. Mean wall thickness and formation periods of trabecular bone packets in idiopathic osteoporosis. Calcif Tissue Int 1981;33:199-204.

  • Parsons JA Potts JT Jr. Physiology and chemistry of parathyroid hormone. Clin Endocrino Metab 1972;1:33-78.

  • Canalis E Centrella M Burch W McCarthy TL. Insulinlike growth factor I mediates selective anabolic effects of parathyroid hormone in bone cultures. J Clin Invest 1989;8:60-5.

  • Neer RM Arnaud CD Zanchetta JR Prince R Gaich GA Reginster JY Hodsman AB Eriksen EF Ish-Shalom S Genant HK Wang O Mitlak BH. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. New Engl J Med 2001;344:1434-41.

  • Hirano T Burr DB Turner CH Sato M Cain RL Hock JM. Anabolic effects of human biosynthetic parathyroid hormone fragment (1-34) LY333334 on remodeling and mechanical properties of cortical bone in rabbits. J Bone Miner Res 1999;14:536-45.

  • Dempster DW Cosman F Kurland ES Zhou H Nieves J Woelfert L Shane E Plavetic K Muller R Bilezikian J Lindsay R. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 2001;16:1846-53.

  • Lau KH Farley JR Freeman TK Baylink DJ. A proposed mechanism of the mitogenic action of fluoride on bone cells: inhibition of the activity of an osteoblastic acid phosphatase. Metabolism 1989;38:858-68.

  • Finkelstein JS Hayes A Hunzelman JL Wyland JJ Lee H Neer RM. The effects of parathyroid hormone alendronate or both in men with osteoporosis. New Engl J Med 2003;349:1216-26.

  • Ettinger B San Martin JA Crans GG Pavo I 2004 Differential effects of teriparatide after treatment with raloxifene or alendronate. J Bone Miner Res19:745-51.

  • Cosman F Nieves J Woelfert L Shen V Lindsay R Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women. J Bone Miner Res 1998;13:1051-5.

  • Black DM Greenspan SL Ensrud KE Palermo L McGowan JA Lang TF Garnero P Bouxsein ML Bilezikian JP Rosen CJ; PaTH Study Investigators The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. New Engl J Med 2003;349:1207-15.

  • Whitfield JF. The bone growth-stimulating PTH and osteosarcoma. Medscape Womens Health 2001;6:7.

  • Farley JR Wergedal JE Baylink DJ. Fluoride directly stimulates proliferation and alkaline phosphatase activity of bone-forming cells. Science 1983;222:330-2.

  • Riggs BL Hodgson SF O'Fallon WM Chao EY Wahner HW Muhs JM Cedel SL Melton LJ 3rd. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. New Engl J Med 1990;322:802-9.

  • Kleerekoper M Peterson EL Nelson DA Phillips E Schork MA Tilley BC Parfitt AM. A randomized trial of sodium fluoride as a treatment for postmenopausal osteoporosis. Osteoporosis Int 1991;1:155-61.

  • Meunier PJ Roux C Seeman E Ortolani S Badurski JE Spector TD Cannata J Balogh A Lemmel EM Pors-Nielsen S Rizzoli R Genant HK Reginster JY. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. New Engl J Med. 2004;350:459-68.

  • Boivin G Deloffre P Perrat B Panczer G Boudeulle M Mauras Y Allain P Tsouderos Y Meunier PJ. Strontium distribution and interactions with bone mineral in monkey iliac bone after strontium salt (S 12911) administration. J Bone Miner Res 1996;11:1302-11.

  • Marie PJ Amman P Boivin G Rey C. Mechanisms of action and therapeutic potential of strontium in bone. Calcif Tissue Int 2001;69:121-29.

  • Delannoy P Bazot D Marie PJ. Long-term treatment with strontium ranelate increases vertebral bone mass without deleterious effect in mice. Metabolism 2002;51:906-11.

  • Marie PJ Hott M Modrowski D De Pollak C Guillemain J Deloffre P Tsouderos Y. An uncoupling agent containin strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats. J Bone Miner Res 1993;9:607-15.

  • Boivin G Meunier PJ. The mineralization of bone tissue: a forgotten dimension in osteoporosis research. Osteoporosis Int 2003;14(Suppl 3):S19-24.

  • Reginster JY Seeman E De Vernejoul MC Adami S Compston J Phenekos C Devogelaer JP Curiel MD Sawicki A Goemaere S Sorensen OH Felsenberg D Meunier PJ. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of peripheral osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005;90:2816-22.

  • Meunier PJ Slosman DO Delmas PD Sebert JL Brandi ML Albanese C Lorenc R Pors-Nielsen S De Vernejoul MC Roces A Reginster JY. Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis-a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab 2002;87:206-6.

  • Quarles LD. Cation sensing receptors in bone: A novel paradigm for regulation bone remodeling? J Bone Miner Res 1997;12:1971-4.

  • Baron R. Biology of the osteoclast. U: Mundy GR Martin TJ urednici. Physiology and Pharmacology of Bone. Handbook of Experimental Pharmacology; Berlin: Springer-Verlag; 1993. str. 111-47.

  • Yoshida H Hayashi S Kunisada T Ogawa M Nishikawa S Okamura H Sudo T Shultz LD Nishikawa S. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature 1990;345:442-4.

  • Felix R Cecchini MG Hofstetter W Elford PR Stutzer A Fleisch H. Impairment of macrophage colonystimulating factor production and lack of resident bone marrow macrophages in the osteopetrotic op/op mouse. J Bone Miner Res 1990;5:781-9.

  • Kodama H Yamasaki A Nose M Niida S Ohgame Y Abe M Kumegawa M Suda T. Congenital osteoclast deficiency in osteopetrotic op/op mice is cured by injections of macrophage colony stimulating factor. J Exp Med 1991;173:269-72.

  • Soriano P Montgomery C Geske R Bradley A. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 1991;64:693-702.

  • Yoneda T Lowe C Lee CH Gutierrez G Niewolna M Williams PJ Izbicka E Uehara Y Mundy GR. Herbimycin A a pp60c-src tyrosine kinase inhibitor inhibits osteoclastic bone resorption in vitro and hypercalcemia in vivo.J Clin Invest 1993;91:2791-5.

  • Fisher JE Caulfield MP Sato M Quartuccio HA Gould RJ Garsky VM Rodan GA Rosenblatt M. Inhibition of osteoclastic bone resorption in vivo by echistatin an "arginylglycyl-aspartyl" (RDG) containing peptide. Endocrinology 1993;132:1411-3.

  • Engleman VW Nickols GA Ross FP Horton MA Griggs DW Settle SL Ruminski PG Teitelbaum SL. A peptidomimetic antagonist of the αv β3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo.J Clin Invest 1997;99:2284-92.

  • Horton MA Davies J. Perspectives-adhesion receptors in bone. J. Bone Miner Res 1989;4:803-8.

  • Vaes E. The action of parathyroid hormone on the excretion and synthesis of lysosomal enzymes and on the extracellular release of acid by bone cells. J Cell Biol 1968;39:676-97.

  • Eilon G Raisz LG. Comparison of the effects of stimulators and inhibitors of resorption on the release of lysosomal enzymes and radioactive calcium from fetal bone in organ culture. Endocrinology 1978;103:1969-75.

  • Bossard MJ Tomaszek TA Thompson SK Amegadzie BY Hanning CR Jones C Kurdyla JT McNulty DE Drake FH Gowen M Levy MA. Proteolytic activity of human osteoclast cathepsin K-expression purification activation and substrate identification. J Biol Chem 1996;271:12517-24.

  • Drake FH Dodds RA James IE Connor JR Debouck C Richardson S Lee-Rykaczewski E Coleman L Rieman D Barthlow R Hastings G Gowen M. Cathepsin K but not cathepsin B L or S is abundantly expressed in human osteoclasts. J Biol Chem 1996;271:12511-6.

  • Min H Morony S Sarosi I Dunstan CR Capparelli C Scully S Van G Kaufman S Kostenuik PJ Lacey DL Boyle WJ Simonet WS. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 2000;192:463-74.

  • Oyajobi BO Anderson DM Traianedes K Williams PJ Yoneda T Mundy GR. Therapeutic efficacy of soluble RANK-IgG Fc (RANK.Fc) fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy. Cancer Res 2001;61:2572-8.

  • Boyce BF Yoneda T Lowe C Soriano P Mundy GR. Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice. J Clin Invest 1992;90:1622-7.

  • Lowe C Yoneda T Boyce BF Chen H Mundy GR Soriano P. Osteopetrosis in Src-deficient mice is due to an autonomous defect of osteoclasts. Proc Natl Acad Sci USA 1993;90:4485-9.

  • Abu-Amer Y Tondravi MM. NFkappaB and bone: the breaking point. Nat Med 1997;3:1189-90.

  • Garrett IR Chen D Gutierrez G Zhao M Escobedo A Rossini G Harris SE Gallwitz W Kim KB Hu S Crews CM Mundy GR. Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J Clin Invest 2003;111:1771-82.

  • Tremollieres FA Pouilles JM Ribot C. Vertebral postmenopausal bone loss is reduced in overweight women: a longitudinal study in 155 early postmenopausal women. J Clin Endocrinol Metab 1993;77:683-6.

  • Ducy P Amling M Takeda S Priemel M Schilling AF Beil FT Shen J Vinson C Rueger JM Karsenty G. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 2000;100:197-207.

  • Felson DT Zhang Y Hannan MT Anderson JJ. Effects of weight and body mass indeks on bone mineral density in men and women: the Framingham Study. J Bone Miner Res 1993;8:567-73.

  • Martin TJ Sims NA. Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol Med 2005;11:76-81.

Search
Journal information
Impact Factor

IMPACT FACTOR 2018: 1.436
5-year IMPACT FACTOR: 1.606

CiteScore 2018: 1.53

SCImago Journal Rank (SJR) 2018: 0.358
Source Normalized Impact per Paper (SNIP) 2018: 0.608

Metrics
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 208 142 1
PDF Downloads 49 32 0